Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates
NEW HAVEN, Conn.--( BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the third quarter ended September 30, 2025, and provided an update on recent company developments.
“In the third quarter, we continued to execute with discipline and focus, advancing our lead program, RLYB116, and achieving a key clinical milestone with the completion of dosing in Cohort 1 in our confirmatory PK/PD Phase 1 study,” said Stephen Uden, M.D., Chief Executive Officer of Rallybio. “In parallel, we strengthened our balance sheet with non-dilutive capital received from the sale of our interest in REV102. With the second cohort of the RLYB116 study progressing, we remain on track to report data in the fourth quarter of 2025 and are increasingly confident in RLYB116's potential to be an effective therapeutic. Our internal and external market assessments further validate the importance of advancing this program, as we plan for the next stage in development and in RLYB116’s potential to address serious unmet needs in complement-mediated diseases.”
Recent Business Highlights and Upcoming Milestones:
Corporate Updates
RLYB116 Program
RLYB332 Program
Third Quarter 2025 Financial Results
About Rallybio
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Rallybio’s pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the timing of dosing of Cohort 2 in the RLYB116 confirmatory PK/PD study and the periods in which data from the trial are expected to be available, whether the PK/PD confirmatory study will demonstrate improved tolerability and complete and sustained inhibition of terminal complement, whether RLYB116 will be effective in treating a broad range of complement-mediated diseases, the potential commercial opportunity for RLYB116, the potential for future development of RLYB332, the potential for RLYB332 to be a best-in-class treatment for diseases of iron overload, and the Company's cash runway. The forward-looking statements in this press release are only predictions and are based largely on management’s current expectations and projections about future events and financial trends that management believes may affect Rallybio’s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the RLYB116 PK/PD confirmatory study, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio’s filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio’s Quarterly Report on Form 10-Q for the period ended June 30, 2025, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.
Financial Tables
RALLYBIO CORPORATION
SELECTED CONDENSED CONSOLIDATED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(Unaudited)
FOR THE THREE MONTHS ENDED
SEPTEMBER 30,
FOR THE NINE MONTHS ENDED
SEPTEMBER 30,
(in thousands, except share and per share amounts)
2025
2024
2025
2024
Revenue:
Collaboration and license revenue
$
212
$
299
$
636
$
598
Total revenue
212
299
636
598
Operating expenses:
Research and development
4,143
8,240
15,942
34,122
General and administrative
2,994
4,125
11,346
15,364
Total operating expenses
7,137
12,365
27,288
49,486
Loss from operations
(6,925
)
(12,066
)
(26,652
)
(48,888
)
Other income:
Interest income
462
986
1,629
3,405
Gain on sale of joint venture and other income
22,479
251
22,771
561
Total other income, net
22,941
1,237
24,400
3,966
Gain (loss) before equity in losses of joint venture
16,016
(10,829
)
(2,252
)
(44,922
)
Loss on investment in joint venture
—
637
874
1,809
Net income (loss)
$
16,016
$
(11,466
)
$
(3,126
)
$
(46,731
)
Net income (loss) per common share, basic and diluted
$
0.36
$
(0.26
)
$
(0.07
)
$
(1.08
)
Weighted-average common shares outstanding, basic and diluted
45,058,591
44,593,221
44,892,485
43,170,177
Other comprehensive gain (loss):
Net unrealized gain (loss) on marketable securities
7
240
(44
)
154
Other comprehensive gain (loss)
7
240
(44
)
154
Comprehensive gain (loss)
$
16,023
$
(11,226
)
$
(3,170
)
$
(46,577
)
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)
SEPTEMBER 30,
2025
DECEMBER 31,
2024
Cash, cash equivalents and marketable securities
$
59,319
$
65,511
Total assets
67,661
68,108
Total liabilities
4,627
6,454
Total stockholders' equity
63,034
61,654